Bifidobacterium Breve BBr16 for Aging-Related Cognitive Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective probiotic products for addressing aging-related cognitive disorders, which are linked to gut-liver axis imbalance and inflammatory responses, and existing treatments do not adequately improve cognitive function or reduce inflammation.
Innovation Solution
A Bifidobacterium breve BBr16 strain, isolated from healthy infants in Bama Yao Autonomous County, Guangxi, is developed, which demonstrates significant improvements in cognitive function and reduces inflammation by increasing neurotransmitter levels and decreasing inflammatory markers when administered to SAMP mice.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotic products are used, then intestinal flora balance is maintained, but aging-related cognitive disorder symptoms are not adequately improved
Solution Approach 1:
The patent identifies and modifies specific parameters of the probiotic strain (Bifidobacterium breve BBr16) including its strain characteristics, metabolic properties, and interaction mechanisms with the gut-liver axis to enhance its efficacy in treating aging-related cognitive disorders. The strain is characterized by specific physiological properties that enable it to cross the blood-brain barrier and exert neuroprotective effects.
Solution Approach 2:
The patent introduces the gut-liver axis as an intermediary mechanism through which the probiotic strain exerts its cognitive protective effects. The Bifidobacterium breve BBr16 strain modulates the gut-liver axis by regulating intestinal flora composition, reducing endotoxemia, and influencing liver function, thereby indirectly improving cognitive function through this intermediary pathway.
2Reliability
If anti-inflammatory treatments are used, then inflammatory markers are reduced, but cognitive function improvement is limited
Solution Approach 1:
The patent converts the harmful inflammatory response into a beneficial effect by using Bifidobacterium breve BBr16 to regulate the gut-liver axis. The strain reduces pro-inflammatory cytokines (TNF-α, IL-6) and increases anti-inflammatory cytokines (IL-10) through modulation of intestinal flora and gut barrier function, thereby transforming the inflammatory pathway into a protective mechanism for cognitive function.
Solution Approach 2:
The patent changes the inflammatory parameter profile by shifting the cytokine balance from pro-inflammatory to anti-inflammatory dominance. The probiotic strain modifies the expression and secretion of inflammatory markers through epigenetic regulation and metabolic product generation, creating a favorable inflammatory environment for cognitive health.
3Stability of the object's composition
If intestinal flora regulation is used, then gut-liver axis balance is improved, but direct cognitive benefit is insufficient
Solution Approach 1:
The patent establishes the gut-liver axis as the intermediary bridge connecting intestinal flora regulation to cognitive function. The Bifidobacterium breve BBr16 strain regulates gut-liver axis balance by modulating intestinal permeability, liver enzyme activity, and circulating metabolites, thereby creating a stable gut-liver axis that directly translates to improved cognitive outcomes through this intermediary system.
Solution Approach 2:
The patent implements a feedback mechanism where the probiotic strain continuously monitors and adjusts gut-liver axis parameters. The strain responds to changes in intestinal flora composition, liver function markers, and cognitive parameters, dynamically regulating its metabolic products and antimicrobial activities to maintain optimal gut-liver axis balance and cognitive function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BBr16 strain effectively decreases aging scores, enhances movement and cognitive abilities, increases neurotransmitter levels, and reduces inflammatory markers, providing a safe and effective treatment for aging-related cognitive disorders.
Implementation Method 1
Bifidobacterium can also produce multiple bacteriostatic components such as an acidic substance, an antimicrobial peptide and a biological enzyme, thereby inhibiting the growth and activity of a pathogenic bacterium
Data Source
AI summary
Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.